Brigitte Robertson
Chief Tech/Sci/R&D Officer chez Yumanity, Inc.
Profil
Brigitte Robertson is currently the Chief Medical Officer at Yumanity, Inc. She previously worked as the Senior Director & Development Strategy Team Lead at Shire Pharmaceuticals, Inc. from 2010 to 2014, and as the Chief Medical Officer at Neurovance, Inc. from 2014 to 2015.
She also held a position as Principal at Children's Community Pediatrics in 2001.
Dr. Robertson received her undergraduate degree from Georgia State University and her doctorate from Georgia Health Sciences University.
Postes actifs de Brigitte Robertson
Sociétés | Poste | Début |
---|---|---|
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Brigitte Robertson
Sociétés | Poste | Fin |
---|---|---|
Neurovance, Inc.
Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/12/2015 |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01/07/2014 |
YUMANITY THERAPEUTICS | Chief Tech/Sci/R&D Officer | - |
Children's Community Pediatrics | Corporate Officer/Principal | 02/01/2001 |
Formation de Brigitte Robertson
Georgia State University | Undergraduate Degree |
Georgia Health Sciences University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 5 |
---|---|
Neurovance, Inc.
Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Neurovance, Inc. operates as a a biopharmaceutical company. It develops treatments for central nervous system disorders. The company was founded by Anthony McKinney and Franklin P. Bymaster in 2011 and is headquartered in Cambridge, MA. | Commercial Services |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Children's Community Pediatrics | |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Health Technology |
Yumanity Therapeutics, Inc.
Yumanity Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA. | Health Technology |